Skip to main content
Source Id
395

Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2014 Average Sales Prices

2017
OEI03-16-00540
Inspection / Evaluation
Department of Health & Human Services OIG
Department of Health & Human Services

When Congress established average sales price (ASP) as the basis for Medicare Part B drug reimbursement, it also provided a mechanism for monitoring market prices and limiting potentially excessive payment amounts. The Social Security Act mandates that OIG compares ASPs with average manufacturer...

As Funding for BPA Research Increased, NIEHS Followed Its Peer Review Process While Also Exercising Its Discretion

2017
OEI-01-15-00150
Inspection / Evaluation
Department of Health & Human Services OIG
Department of Health & Human Services

Bisphenol-A (BPA), a chemical often used to produce food and drink packaging, has been linked to a variety of adverse health conditions, including cancer. The National Institute of Environmental Health Sciences (NIEHS) funds studies that test substances, including BPA, for carcinogenicity and other...

Medicare Shared Savings Program Accountable Care Organizations Have Shown Potential for Reducing Spending and Improving Quality

2017
OEI-02-15-00450
Inspection / Evaluation
Department of Health & Human Services OIG
Department of Health & Human Services

Medicare spending is expected to grow to $1.4 trillion by 2027. To control this increase and promote quality and healthy populations, the Centers for Medicare & Medicaid Services (CMS) has implemented and is considering a number of alternative payment models that reward providers for the quality and...

Colorado State Medicaid Fraud Control Unit: 2016 Onsite Review

2017
OEI-06-16-00520
Inspection / Evaluation
Department of Health & Human Services OIG
Department of Health & Human Services

OIG administers the Medicaid Fraud Control Unit (MFCU or Unit) grant awards, annually recertifies the Units, and oversees the Units' performance in accordance with the requirements of the grant. As part of this oversight, OIG conducts periodic reviews of all Units and prepares public reports based...

FDA Oversight of Tobacco Manufacturing Establishments

2017
OEI-01-15-00300
Inspection / Evaluation
Department of Health & Human Services OIG
Department of Health & Human Services

Smoking is the leading cause of preventable disease and death in the United States. In 2009, Congress passed the Family Smoking Prevention and Tobacco Control Act, authorizing FDA to begin regulating tobacco products in the United States. It granted FDA comprehensive authority over domestic tobacco...

HHS's Office of Refugee Resettlement Improved Coordination and Outreach to Promote the Safety and Well-Being of Unaccompanied Alien Children

2017
OEI-09-16-00260
Inspection / Evaluation
Department of Health & Human Services OIG
Department of Health & Human Services

Each year, tens of thousands of children without legal status enter the United States unaccompanied by their parents or legal guardians. These children are referred to as unaccompanied alien children (UAC). Between fiscal years 2012 and 2016, the number of UAC entering the United States increased...

OHRP Generally Conducted Its Compliance Activities Independently, But Changes Would Strengthen Its Independence

2017
OEI-01-15-00350
Inspection / Evaluation
Department of Health & Human Services OIG
Department of Health & Human Services

Protecting the rights of human subjects-individuals who volunteer to participate in research-is critical to ensuring their safety and public confidence in research conducted or supported by the Department of Health and Human Services (HHS). OHRP enforces compliance with HHS regulations for...

Opioids in Medicare Part D: Concerns about Extreme Use and Questionable Prescribing

2017
OEI-02-17-00250
Inspection / Evaluation
Department of Health & Human Services OIG
Department of Health & Human Services

Opioid abuse and overdose deaths are at epidemic levels in the United States. This data brief is part of a larger strategy by the OIG to fight the opioid crisis and address one of its top priority outcomes-to protect beneficiaries from prescription drug abuse. It provides baseline data on the extent...

Part D Plans Generally Include Drugs Commonly Used by Dual Eligibles: 2017 

2017
OEI-05-17-00160
Inspection / Evaluation
Department of Health & Human Services OIG
Department of Health & Human Services

This report fulfills for 2017 the annual reporting mandate from the Patient Protection and Affordable Care Act (ACA) for 2017. The ACA requires OIG to conduct a study of the extent to which formularies used by Medicare Part D plans include drugs commonly used by full benefit dual eligible...

T-MSIS Data Not Yet Available for Overseeing Medicaid

2017
OEI-05-15-00050
Inspection / Evaluation
Department of Health & Human Services OIG
Department of Health & Human Services

In 2016, the Federal Government and States spent $574 billion on Medicaid, serving more than 74 million enrolled individuals. Complete, accurate, and timely Medicaid data are vital for the effective administration and oversight of the Medicaid program by States and the Federal Government...

Subscribe to Department of Health & Human Services